{"unnormalised": "New Delhi, India - In a landmark ruling concerning intellectual property rights, the Delhi High Court on 22/07/2024 granted an injunction against a local manufacturer, M/s Sharma Industries, for infringing the patent of a multinational pharmaceutical company, Pfizer Inc. The case, filed under Section 104 of the Patents Act, 1970, pertained to a drug used in the treatment of diabetes, patented under patent no. 254321.", "normalised": "New Delhi, India - In a landmark ruling concerning intellectual property rights, the Delhi High Court on twenty second july two thousand and twenty four granted an injunction against a local manufacturer, M slash s Sharma Industries, for infringing the patent of a multinational pharmaceutical company, Pfizer Inc. The case, filed under Section one hundred and four of the Patents Act, one thousand nine hundred and seventy, pertained to a drug used in the treatment of diabetes, patented under patent number two hundred and fifty four thousand three hundred and twenty one."}
{"unnormalised": "Advocate Rohan Verma, representing Pfizer, argued that Sharma Industries was producing a generic version of the drug without obtaining the necessary licenses, causing significant financial loss to his client, estimated at Rs. 5 crores. The defendant, represented by Sr. Adv. Mehra, contended that their version of the drug was substantially different and did not infringe on Pfizer's patent, citing technical specifications Doc ID: 789654 in their defense.", "normalised": "Advocate Rohan Verma, representing Pfizer, argued that Sharma Industries was producing a generic version of the drug without obtaining the necessary licenses, causing significant financial loss to his client, estimated at rupee five crore. The defendant, represented by Senior Advocate Mehra, contended that their version of the drug was substantially different and did not infringe on Pfizer's patent, citing technical specifications Document I D: seven hundred and eighty nine thousand six hundred and fifty four in their defense."}
{"unnormalised": "Justice Malhotra, presiding over the case, ruled in favor of Pfizer, citing expert testimony and laboratory analysis that demonstrated a clear infringement. The court ordered Sharma Industries to cease production and sale of the infringing drug with immediate effect and awarded damages of Rs. 2.5 crore to Pfizer, payable within 90 days.", "normalised": "Justice Malhotra, presiding over the case, ruled in favor of Pfizer, citing expert testimony and laboratory analysis that demonstrated a clear infringement. The court ordered Sharma Industries to cease production and sale of the infringing drug with immediate effect and awarded damages of rupee two point five crore to Pfizer, payable within ninety days."}
{"unnormalised": "The judgement underscores the importance of protecting intellectual property rights in the Indian pharmaceutical sector and sends a strong message to companies engaging in patent infringement. Legal experts predict that this ruling may serve as a precedent for similar cases involving intellectual property disputes, especially relating to pharmaceuticals and technology.", "normalised": "The judgement underscores the importance of protecting intellectual property rights in the Indian pharmaceutical sector and sends a strong message to companies engaging in patent infringement. Legal experts predict that this ruling may serve as a precedent for similar cases involving intellectual property disputes, especially relating to pharmaceuticals and technology."}
